Fluorescence PCR · Pharmacogenetics
Human CYP2C19 Gene Polymorphism Detection Kit (Fluorescence PCR)
Qualitative detection of CYP2C19 *2, *3, and *17 gene polymorphisms in genomic DNA from human whole blood samples.
- SKU Code
AENE-GE012A- Approval
- On request
- Product Type
- Assay / Kit
- Status
- Available
Qualitative detection of CYP2C19 *2, *3, and *17 gene polymorphisms in genomic DNA from human whole blood samples.
| Product type | Assay / Kit |
|---|---|
| Technology platform | Fluorescence PCR |
| Application area | Pharmacogenetics |
Certificate
CE/TFDA
Epidemiology
CYP2C19 belongs to the cytochrome P450 family and plays a key role in drug metabolism. It processes numerous endogenous compounds and approximately 2% of clinically used drugs, including antiplatelet agents (e.g., clopidogrel), proton pump inhibitors (omeprazole), and anticonvulsants. Genetic variation in CYP2C19 leads to altered drug-metabolizing capacity. The *2 (rs4244285) and *3 (rs4986893) loss-of-function alleles reduce enzyme activity and substrate metabolism, raising plasma drug levels and increasing the risk of concentration-dependent adverse reactions. In contrast, the *17 (rs12248560) allele enhances CYP2C19 activity, boosting active metabolite formation, which can intensify platelet inhibition and elevate bleeding risk. Individuals with poor metabolizer status who receive standard doses over prolonged periods may experience severe toxicities, including hepatotoxicity, hematopoietic damage, and central nervous system injury, potentially leading to fatal outcomes. Based on metabolic phenotype, patients are classified as: ultrarapid metabolizers (UM: *17/*17, *1/*17), rapid metabolizers (RM: *1/*1), intermediate metabolizers (IM: *1/*2, *1/*3), and poor metabolizers (PM: *2/*2, *2/*3, *3/*3).
Work Flow
For sample preparation, a universal DNA/RNA kit may be employed (compatible with an automatic nucleic acid extractor). Follow the manufacturer's protocol, using 200 µL of sample and an elution volume of 100 µL.
Alternatively, a genomic DNA purification kit (catalog number A1120) or a nucleic acid extraction/purification reagent (YDP348) can be used. Adhere to the respective extraction instructions, with a recommended input volume of 200 µL and an elution volume of 160 µL.
| SKU code | AENE-GE012A |
|---|---|
| Storage | Liquid: ≤-18℃ |
| Shelf-life | 12 months |
| Specimen Type | Fresh EDTA anticoagulated blood |
| CV | ≤5.0% |
| LoD | 1.0ng/μL |
| Specificity | There is no cross-reactivity with other highly consistent sequences (CYP2C9 gene) in the human genome. The mutations of CYP2C19*23, CYP2C19*24 and CYP2C19*25 sites outside the detection range of this kit have no effect on the detection effect of this kit. |
| Applicable Instruments | Applied Biosystems 7500 Real-Time PCR Systems Applied Biosystems 7500 Fast Real-Time PCR Systems QuantStudio®5 Real-Time PCR Systems SLAN-96P Real-Time PCR Systems LightCycler®480 Real-Time PCR system LineGene 9600 Plus Real-Time PCR Detection System MA-6000 Real-Time Quantitative Thermal Cycler BioRad CFX96 Real-Time PCR System BioRad CFX Opus 96 Real-Time PCR System |
| Approval | On request |
|---|---|
| Documents | Datasheet, IFU, SDS, COA / conformance, origin, and export documents where available |
FAQ
What should be confirmed before quotation?
Sample context, collection method, and extraction workflow should be confirmed before final kit selection.
Which documents can be requested?
Datasheet, IFU, SDS, COA / conformance, origin, insurance, and export documents can be checked where available.
Can the format be adjusted for different workflows?
Liquid or lyophilized format options should be confirmed together with instrument compatibility and shipment requirements.
Inquiry
Send the essentials for a useful first reply.
Share the application, sample type, format, destination, and expected quantity so AeneBio can route AENE-GE012A to the right quote or sample discussion.